epacadostat

April 3, 2019

DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show

News

Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data from ... Read more

February 8, 2019

IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA

News

IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company now ... Read more

January 16, 2019

Triple Combination Works Well in Recurrent Ovarian Cancer with Smaller Tumors, Study Shows

News

The size of tumors in patients with recurrent ovarian cancer seems to predict responses to a triple combination treatment composed of IMV‘s lead candidate DPX-Survivac, Incyte’s experimental epacadostat, and low-dose chemotherapy, a Phase ... Read more

September 19, 2018

Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors

News

IMV will soon launch a Phase 2 trial to examine the potential of its lead candidate DPX-Survivac in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in five solid tumor types. The study is expected ... Read more

September 12, 2018

IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient

News

The Phase 1b/2 trial investigating IMV lead candidate DPX-Survivac in combination with Incyte‘s experimental epacadostat and low-dose chemotherapy in recurrent ovarian cancer patients has completed patient enrollment in the study’s first part, the ... Read more